Zeckser Jeffrey, Wolff Michael, Tucker Jason, Goodwin Josh
Southwest Spine & Sports, 9913 N. 95th Street, Scottsdale, AZ 85258, USA.
iOrthoBiologix, 12312 Copper Way, Charlotte, NC 28277, USA.
Stem Cells Int. 2016;2016:3908389. doi: 10.1155/2016/3908389. Epub 2016 Jan 11.
Low back pain with resultant loss of function, decreased productivity, and high economic costs is burdensome for both the individual and the society. Evidence suggests that intervertebral disc pathology is a major contributor to spine-related pain and degeneration. When commonly used conservative therapies fail, traditional percutaneous or surgical options may be beneficial for pain relief but are suboptimal because of their inability to alter disc microenvironment catabolism, restore disc tissue, and/or preserve native spine biomechanics. Percutaneously injected Multipotent Mesenchymal Stem Cell (MSC) therapy has recently gained clinical interest for its potential to revolutionarily treat disc-generated (discogenic) pain and associated disc degeneration. Unlike previous therapies to date, MSCs may uniquely offer the ability to improve discogenic pain and provide more sustained improvement by reducing disc microenvironment catabolism and regenerating disc tissue. Consistent treatment success has the potential to create a paradigm shift with regards to the treatment of discogenic pain and disc degeneration.
下背部疼痛导致功能丧失、生产力下降以及高昂的经济成本，对个人和社会来说都是沉重的负担。有证据表明，椎间盘病变是脊柱相关疼痛和退变的主要原因。当常用的保守治疗无效时，传统的经皮治疗或手术治疗可能有助于缓解疼痛，但由于无法改变椎间盘微环境的分解代谢、恢复椎间盘组织和/或保留脊柱的天然生物力学，因此并非最佳选择。经皮注射多能间充质干细胞（MSC）疗法最近因其有可能革命性地治疗椎间盘源性（盘源性）疼痛及相关的椎间盘退变而引起了临床关注。与以往的治疗方法不同，间充质干细胞可能具有独特的能力，通过减少椎间盘微环境的分解代谢和再生椎间盘组织来改善盘源性疼痛，并提供更持久的改善效果。持续的治疗成功有可能在盘源性疼痛和椎间盘退变的治疗方面引发范式转变。
